Literature DB >> 27905840

Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Thor A Wagner1,2.   

Abstract

More than 30 million people are infected with HIV, and HIV remains the fifth leading cause of disability-adjusted life years worldwide. Antiretroviral therapy (ART) dramatically decreases mortality rate, but there are side effects, long-term toxicities, expenses, stigmas, and inconveniences associated with chronic treatment, and HIV-infected individuals on ART have an increased risk of malignancies, cardiovascular disease, neurologic disease, and shortened life expectancy. Therefore, a cure for HIV remains an important goal. Combining new cell and gene therapy technology is an exciting approach that appears promising in vitro. Animal testing and careful clinical trials will be needed to determine if these strategies are clinically useful.

Entities:  

Keywords:  CCR5; HIV; cell therapy; chimeric antigen receptor; gene therapy

Mesh:

Year:  2016        PMID: 27905840      PMCID: PMC5144862          DOI: 10.1089/apc.2016.0226

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  84 in total

Review 1.  Neurocognitive dysfunction in the highly active antiretroviral therapy era.

Authors:  Nomvuyo Z Mothobi; Bruce J Brew
Journal:  Curr Opin Infect Dis       Date:  2012-02       Impact factor: 4.915

Review 2.  Developing strategies for HIV-1 eradication.

Authors:  Christine M Durand; Joel N Blankson; Robert F Siliciano
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

Review 3.  HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.

Authors:  Tae-Wook Chun; Anthony S Fauci
Journal:  AIDS       Date:  2012-06-19       Impact factor: 4.177

4.  Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Torsten B Neilands; Colleen F Kelley; Peter W Hunt; Rebecca Hoh; Jeffrey M Linnen; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

5.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

6.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

7.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.

Authors:  Deborah Persaud; Stuart C Ray; Joleen Kajdas; Aima Ahonkhai; George K Siberry; Kimberly Ferguson; Carrie Ziemniak; Thomas C Quinn; Joseph P Casazza; Steven Zeichner; Stephen J Gange; Douglas C Watson
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

9.  Nef-mediated MHC class I down-regulation unmasks clonal differences in virus suppression by SIV-specific CD8(+) T cells independent of IFN-gamma and CD107a responses.

Authors:  Jacob T Minang; Matthew T Trivett; Lori V Coren; Eugene V Barsov; Michael Piatak; David E Ott; Claes Ohlen
Journal:  Virology       Date:  2009-06-24       Impact factor: 3.616

10.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09
View more
  2 in total

1.  HIV Receives a "One Two Knockout Punch".

Authors:  Conrad Russell Cruz; Catherine M Bollard
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

2.  Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.

Authors:  Kumudhini Preethi Haran; Agnes Hajduczki; Mary S Pampusch; Gwantwa Mwakalundwa; Diego A Vargas-Inchaustegui; Eva G Rakasz; Elizabeth Connick; Edward A Berger; Pamela J Skinner
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.